CT lung cancer advocates are breathing easier now that the Centers for Medicare & Medicaid Services (CMS) has issued a preliminary decision to cover low-dose CT lung cancer screening for eligible patients. Still, there are some provisions of the decision that have left many observers wondering whether the CMS decision went far enough and whether it will enable everyone who could benefit from screening to actually get screened.
Recent imaging reimbursement cuts have correlated with a shift of more outpatient MRI exams being performed in hospital outpatient departments than private offices, according to a study published online in the Journal of the American College of Radiology.
While healthcare systems and general practitioners get much of the attention when it comes to undergoing Meaningful Use audits, radiologists should be prepared to come under the same scrutiny, as well.
The diagnostic imaging system market will experience only modest growth over the next decade, mainly due to healthcare reform in the U.S., according to a new report from Decision Resources Group.
Despite a negative recommendation from its own review panel, the Centers for Medicare & Medicaid Services on Monday issued a proposed decision memo approving low-dose CT screening for Medicare patients.
The Centers for Medicare & Medicaid Services' recently released final rule for the 2015 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment Systems has some significant implications for medical imaging.
The week ahead should be a big one for lung cancer screening advocates, and not just because we're in the midst of Lung Cancer Awareness Month.
Proton beam therapy is going through an interesting period right now.
Costs associated with proton therapy are similar to--and in some cases less than--a number of conventional radiotherapy techniques used to treat early stage breast cancer, according to research from the University of Texas MD Anderson Proton Therapy Center.
A study of the utilization rates and estimated Medicare costs of lung cancer diagnostic workups in patients who had abnormal CT scans shows that nearly half of the costs were attributed to biopsies that ultimately proved to be negative for lung cancer.